Colchicine for the treatment of COVID-19

Mikołajewska, Agata; Fischer, Anna-Lena; Piechotta, Vanessa; Mueller, Anika; Metzendorf, Maria‐Inti; Becker, Michele Michelin; Dorando, Elena; Pacheco, Rafael Leite; Martimbianco, Ana Luiza Cabrera; Riera, Rachel; Skoetz, Nicole; Stegemann, Miriam

doi:10.1002/14651858.cd015045

Cited by 46 publications

(46 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the benefit was not confirmed in the subgroup analysis including RCTs [ 97 ]. A Cochrane meta-analysis including three RCTs (11,525 hospitalized patients and 1 RCT with 4,488 non-hospitalized subjects) concluded that colchicine has little or no effect on mortality or clinical progression compared with placebo or standard-of-care alone in patients hospitalized with moderate-to-severe COVID-19 [ 98 ]. Indeed, available findings from RCTs are certainly influenced by different sample size, different endpoints, and different follow-up.…”

Section: Colchicine To Treat Covid-19: What Is the Rationale?mentioning

confidence: 99%

Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation

et al. 2022

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is capable of inducing the activation of NACHT, leucinerich repeat, and pyrin domain-containing protein 3 (NLRP3) inflammasome, a macromolecular structure sensing the danger and amplifying the inflammatory response. The main product processed by NLRP3 inflammasome is interleukin (IL)-1β, responsible for the downstream production of IL-6, which has been recognized as an important mediator in coronavirus disease 2019 . Since colchicine is an anti-inflammatory drug with the ability to block NLRP3 inflammasome oligomerization, this may prevent the release of active IL-1β and block the detrimental effects of downstream cytokines, i.e. IL-6. To date, few randomized clinical trials and many observational studies with colchicine have been conducted, showing interesting signals. As colchicine is a nonspecific inhibitor of the NLRP3 inflammasome, compounds specifically blocking this molecule might provide increased advantages in reducing the inflammatory burden and its related clinical manifestations. This may occur through a selective blockade of different steps preceding NLRP3 inflammasome oligomerization as well as through a reduced release of the main cytokines . Since most evidence is based on observational studies, definitive conclusion cannot be drawn and additional studies are needed to confirm preliminary results and further dissect how colchicine and other NLRP3 inhibitors reduce the inflammatory burden and evaluate the timing and duration of treatment.

show abstract

Section: Colchicine To Treat Covid-19: What Is the Rationale?mentioning

confidence: 99%

Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation

et al. 2022

View full text Add to dashboard Cite

show abstract

“…However, colchicine was associated with increased risk of gastrointestinal side effects and rates of pulmonary embolism and no significant differences in mortality [ 118 , 119 , 122 ]. Despite enthusiasm from a small initial Italian study showing mortality benefit in patients receiving colchicine compared to standard care, the majority of evidence to-date, including several larger trials and meta-analyses, have found no significant mortality benefit for colchicine [ 118 , [120] , [121] , [122] , [123] , [124] , [125] , [126] ]. At this time, there is insufficient evidence to support the use of colchicine in COVID-19 patients.…”

Section: Discussionmentioning

confidence: 99%

Clinical update on COVID-19 for the emergency and critical care clinician: Medical management

Long¹,

Chavez²,

Carius³

et al. 2022

The American Journal of Emergency Medicine

View full text Add to dashboard Cite

“…Hydroxychloroquine (130) Reduces activity of immune system by disrupting lysosomal stability NCT04332991 Colchicine (131) Anti-inflammatory NCT04326790 Alvelestat (132) Neutrophil Elastase inhibitor NCT00769119…”

Section: Discussionmentioning

confidence: 99%

Neutrophil Extracellular Traps, Sepsis and COVID-19 – A Tripod Stand

et al. 2022

View full text Add to dashboard Cite

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the current coronavirus disease 2019 (COVID-19) pandemic. Majority of COVID-19 patients have mild disease but about 20% of COVID-19 patients progress to severe disease. These patients end up in the intensive care unit (ICU) with clinical manifestations of acute respiratory distress syndrome (ARDS) and sepsis. The formation of neutrophil extracellular traps (NETs) has also been associated with severe COVID-19. Understanding of the immunopathology of COVID-19 is critical for the development of effective therapeutics. In this article, we discuss evidence indicating that severe COVID-19 has clinical presentations consistent with the definitions of viral sepsis. We highlight the role of neutrophils and NETs formation in the pathogenesis of severe COVID-19. Finally, we highlight the potential of therapies inhibiting NETs formation for the treatment of COVID-19.

show abstract

Colchicine for the treatment of COVID-19

Cited by 46 publications

References 58 publications

Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation

Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation

Clinical update on COVID-19 for the emergency and critical care clinician: Medical management

Neutrophil Extracellular Traps, Sepsis and COVID-19 – A Tripod Stand

Contact Info

Product

Resources

About